Registration Options

Activity Dates: 11/22/2019 - 10/30/2022

This course is closed. Please look for other available products in AAPP Education+Resources.

Target Audience

If you are a pharmacist or other health care professional involved in the comprehensive medication management and/or care of patients at risk for tardive dyskinesia due to antipsychotic medications, we invite you to participate in this online course.

Session Summary

This presentation includes a review of pathophysiology and differential diagnosis of tardive dyskinesia (TD), VMAT2 inhibitor mechanism of action in managing TD, and a review of the comparative pharmacology, pharmacokinetic, efficacy and safety of available VMAT2 inhibitors.

© CPNP, All rights reserved

Course Requirements

You will proceed through the following steps to satisfactorily complete this course:

  • Sign in (or create a FREE account).
  • Register for this course.
  • Review the full content of the activity and reflect upon its teachings.
  • Complete the post-test at the end of the activity no later than the closing activity date.
  • Complete the evaluation at the end of the activity.
  • If necessary, complete the post-test retest no later than the closing activity date.
  • Receive a passing grade (70%).
  • Provide the necessary details in your profile to ensure correct reporting by AAPP to CPE Monitor.

Participants in this course must complete an examination and achieve a score of 70% or greater. Up to two exam attempts are provided to each participant. Successful completion of the course also requires the completion of a course evaluation. Upon successful completion, ACPE credit is reported immediately to CPE Monitor although transcripts can be retrieved by participants online at

Faculty Information and Disclosures

Stephen R. Saklad, PharmD, BCPP
Steve Stoner, RPh, PharmD, BCPP

View biographical information and disclosures

Learning Objectives

  1. Review pathophysiology and differential diagnosis of tardive dyskinesia.
  2. Demonstrate an understanding of the mechanism of action of VMAT2 inhibitors in tardive dyskinesia.
  3. Explain the comparative pharmacology, pharmacokinetic, efficacy and safety of available VMAT2 inhibitors.


Continuing Education Credit and Disclosures

Activity Dates: 11/22/2019 - 10/30/2022
ACPE Contact Hours: 1.25
ACPE Number: 0284-0000-19-044-H01-P (Knowledge)
Nursing Credit Reminder: Note that ACPE credit is accepted for certification renewal.

ACPEThe College of Psychiatric and Neurologic Pharmacists is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

View AAPP's Privacy Policy

AAPP owns the copyright, is licensed or has received permissions for use of, or is otherwise permitted to use copyrighted materials within any CPE activity. Authors and speakers are required to obtain necessary copyright permissions for content in CPE activities. AAPP complies with copyright laws and regulations.

Questions? Contact AAPP.

Grant Support

This activity has been supported through an independent educational grant from Neurocrine Biosciences Inc. and Teva Pharmaceuticals.
© CPNP, All rights reserved